August 21, 2026

Merck and Moderna report first positive Phase 3 for individualised mRNA cancer therapy

Merck and Moderna announced a positive Phase 3 readout for their individualised neoantigen therapy, in which algorithms select target mutations from a patient's tumour sequencing data and a bespoke mRNA construct is manufactured per patient. It is the first Phase 3 win for a treatment that depends on computational target selection.